Richard Stone, Md

This early-phase trial tests a new drug called revumenib added to standard chemotherapy and a targeted therapy (midostaurin) for people with a specific genetic type of acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it works to put the cancer into r…